Trivedi et al., (2013) undertook a study of to evaluate the efficacy and safety of lisdexamfetamine augmentation for major depressive disorder (MDD) in escitalopram nonremitters.
Trivedi et al., (2013) undertook a study of toevaluate the efficacy and safety of lisdexamfetamine augmentationfor major depressive disorder (MDD) in escitalopram nonremitters.